KEY tAKEAWAYS: fiE HOSTED A MINI-SERIES OF FIRESIDE CHATS LAST WEEK FOCUSED ON

ANTIBODIES, OUR THREE TAKES INCLUDE: 1) ffi-MaBS, BEYOND THEIR LOOMING APPROVAL OF A

DIFFERENTIATED Gd2 TARGETED ANTIBODY AND POTENTIALLY NEW RADIO-LABELED TECHNOLOGY FOR

MaBS, WE WOULD FOCUS ON INITIAL DATA FOR THEIR Gd2X¢d3 BISPECIFIC IN dECEMBER – WE

HAVE PREVIEWED THIS DATA ON PAGE 17; 2) ¢YTOMfl, WE ARE INTRIGUED BY THE POTENTIAL OF

CytomX’s prodrug-LIKE TECHNOLOGY FOR ANTIBODY-DRUG CONJUGATES, WITH A POTENTIAL

CLUSTER OF DATA IN 2021 ACROSS TWO DIFFERENT CANDIDATES IN MULTIPLE TUMOR TYPES — SEE

OUR PREVIEW FOR ¢fl-2029 (¢d71 ad¢) DATA ON PAGE 5; 3) flENCOR, WE ARE INTRIGUED BY

THE INITIAL DATA BEING DEVELOPED BY THEIR BISPECIFIC PLATFORM FOR io-io COMBOS AND t CELL

RECRUITING. iN FIGURE 1, WE HIGHLIGHT 20 CATALYSTS ASSOCIATED WITH ANTIBODIES FOR OUR

STOCKS — including updated data from MacroGenics’ flotetuzumab in AML (previewed

ON PAGE 8), AND THE MOST IMPORTANT CATALYST COULD BE INITIAL ANTI-tiGit COMBINATION

DATA FROM aRCUS (PREVIEWED ON PAGE 11). fiE REITERATE OUR oVERWEIGHT RATINGS ON

ffimab, AND r¢Us.